Plasma magnesium and the risk of new-onset hyperuricemia in hypertensive patients.

We aimed to evaluate the relationship of plasma magnesium with the risk of new-onset hyperuricemia, and examine any possible effect modifiers in hypertensive patients. This is a post-hoc analysis of the Uric acid (UA) Sub-study of the China Stroke Primary Prevention Trial (CSPPT). A total of 1685 participants were included in the current study. The main outcome was new-onset hyperuricemia defined as a UA concentration >/=417 mumol/L in men or >/=357 mumol/L in women. The secondary outcome was a change in UA concentration defined as UA at the exit visit minus that at baseline. During a median follow-up duration of 4.3 years, new-onset hyperuricemia occurred in 290 (17.2%) participants. There was a significantly inverse relation of plasma magnesium with the risk of new-onset hyperuricemia (per SD increment; OR, 0.85; 95%CI: 0.74, 0.99) and change in UA levels (per SD increment; beta, -3.96 mumol/L; 95%CI: -7.14, -0.79). Consistently, when plasma magnesium was analyzed as tertiles, a significantly lower risk of new-onset hyperuricemia (OR, 0.67; 95%CI: 0.48, 0.95) and less increase in UA levels (beta, -8.35mumol/L; 95%CI: -16.12, -0.58) were found among participants in tertile 3 (>/=885.5 mumol/L) compared with those in tertile 1 (<818.9 mumol/L). Similar trends were found in males and females. Higher plasma magnesium levels were associated with a decreased risk of new-onset hyperuricemia in hypertensive adults.